|
Orphan Medical must know how it feels to be all alone. The firm buys, earns approval for, and markets drugs for inadequately treated or rare diseases, taking advantage of incentives offered under the Orphan Drug Act of 1983. The company focuses on therapies for sleep disorders, pain management, and central nervous system diseases. It typically acquires drug candidates in Phase II or III trials that are a significant improvement over existing therapies. Orphan Medical's lead candidate is Xyrem, a treatment for narcolepsy. Other candidates include Antizol, and antidote for ethylene ingestion, and Butamben, which treats pain associated with cancer. Jazz Pharmaceuticals bought the company in mid-2005.
|
| | | Contact Information | |
Address: |
13911 Ridgedale Dr., Ste. 250
Minnetonka, MN 55305
| | Phone: | 952-513-6900 | | Fax: | 952-541-9209 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2004): | 23.80 M | | Revenue Growth (1 yr): | 53.50% | | Employees (2004): | 80 | | Employee Growth (1 yr): | (-5.90%) |
|
|
Key People
| | • |
Chairman, CEO, and Secretary:
John Howell Bullion
|
|
|
